Protalix BioTherapeutics (PLX) FCF Margin Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,469.00 |
| Dec 31, 2025 | 7,015.00 |
| Sep 30, 2025 | 1,065.00 |
| Jun 30, 2025 | 3,797.00 |
| Mar 31, 2025 | -2,105.00 |
| Dec 31, 2024 | 4,801.00 |
| Sep 30, 2024 | 4,415.00 |
| Jun 30, 2024 | 1,926.00 |
| Mar 31, 2024 | 16,711.00 |
| Dec 31, 2023 | 24,331.00 |
| Sep 30, 2023 | -210,614.00 |
| Jun 30, 2023 | 41,783.00 |
| Mar 31, 2023 | 17,836.00 |
| Dec 31, 2022 | -99,714.00 |
| Sep 30, 2022 | 7,764.00 |
| Jun 30, 2022 | 5,637.00 |
| Mar 31, 2022 | 49,502.00 |
| Dec 31, 2021 | 29,403.00 |
| Sep 30, 2021 | 5,840.00 |
| Jun 30, 2021 | 79,645.00 |
| Mar 31, 2021 | 131,163.00 |
| Sep 30, 2020 | 71,670.00 |
| Jun 30, 2020 | 26,996.00 |
| Mar 31, 2020 | 33,715.00 |
| Mar 31, 2019 | 5,715.00 |
| Dec 31, 2018 | -19,162.00 |
| Sep 30, 2018 | 241,551.00 |
| Jun 30, 2018 | -1,519.00 |
| Mar 31, 2018 | 7,445.00 |
| Dec 31, 2017 | 83,360.00 |
| Sep 30, 2017 | 9,287.00 |
| Jun 30, 2017 | -18,807.00 |
| Mar 31, 2017 | -34,903.00 |
| Dec 31, 2016 | -4,903.00 |
| Sep 30, 2016 | 72,986.00 |
| Jun 30, 2016 | 11,666.00 |
| Mar 31, 2016 | -124,222.00 |
| Sep 30, 2015 | -40,485.00 |